Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
NEW YORK, May 12, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc. ("Puma Biotechnology") (NASDAQ:PBYI) securities between February 29, 2016 and May 4, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/puma-biotechnology-inc?wire=1. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company did not anticipate that the U.S. Food and Drug Administration (“FDA”) would ultimately approve PB272 (“neratinib”) for the treatment of breast cancer; (ii) as such, Puma Biotechnology had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Puma Biotechnology you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/puma-biotechnology-inc?wire=1.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
